Related Experiment Video
Updated: Mar 18, 2026
Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
Compound K Attenuates the Development of Atherosclerosis in ApoE(-/-) Mice via LXRα Activation
Li Zhou1,2, Yu Zheng3, Zhuoying Li4
1Institute of Materia Medica and Department of Pharmaceutics, College of Pharmacy, Third Military Medical University, Shapingba, Chongqing 400038, China. zl1007@tmmu.edu.cn.
Background:
Atherosclerosis is a fundamental pathological process responded to some serious cardiovascular events. Although the cholesterol-lowering drugs are widely prescribed for atherosclerosis therapy, it is still the leading cause of death in the developed world. Here we measured the effects of compound K in atherosclerosis formation and investigated the probably mechanisms of the anti-antherosclerosis roles of compound K.
Methods:
We treated the atherosclerotic model animals (apoE(-/-) mice on western diet) with compound K and measured the size of atherosclerotic lesions, inflammatory cytokine levels and serum lipid profile. Peritoneal macrophages were collected in vitro for the foam cell and inflammasome experiments.
Results:
Our results show that treatment with compound K dose-dependently attenuates the formation of atherosclerotic plaques by 55% through activation of reverse cholesterol transport pathway, reduction of systemic inflammatory cytokines and inhibition of local inflammasome activity. Compound K increases the cholesterol efflux of macrophage-derived foam cells, and reduces the inflammasome activity in cholesterol crystal stimulated macrophages. The activation of LXRα may contribute to the athero-protective effects of compound K.
Conclusion:
These observations provide evidence for an athero-protective effect of compound K via LXRα activation, and support its further evaluation as a potential effective modulator for the prevention and treatment of atherosclerosis.
Insights
Compound K effectively reduces atherosclerosis plaque formation by 55% in animal models. This is achieved by enhancing cholesterol removal and reducing inflammation, suggesting its potential for treating cardiovascular disease.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Molecular Biology
Background:
- Atherosclerosis remains a leading cause of death despite widespread cholesterol-lowering drug use.
- Existing therapies for atherosclerosis have limitations, necessitating novel treatment strategies.
- Understanding the molecular mechanisms underlying atherosclerosis is crucial for developing new interventions.
Purpose of the Study:
- To evaluate the anti-atherosclerosis effects of compound K.
- To investigate the underlying mechanisms of compound K's athero-protective actions.
- To explore compound K as a potential therapeutic agent for atherosclerosis.
Main Methods:
- Atherosclerotic model animals (apoE(-/-) mice on a Western diet) were treated with compound K.
- Measurements included atherosclerotic lesion size, inflammatory cytokine levels, and serum lipid profiles.
- In vitro experiments assessed foam cell cholesterol efflux and inflammasome activity in macrophages.
Main Results:
- Compound K dose-dependently reduced atherosclerotic plaque formation by 55%.
- Treatment activated the reverse cholesterol transport pathway and reduced systemic inflammation.
- Compound K increased macrophage cholesterol efflux and inhibited inflammasome activity, potentially via LXRα activation.
Conclusions:
- Compound K demonstrates significant athero-protective effects.
- LXRα activation is implicated in the beneficial actions of compound K.
- Compound K warrants further investigation as a potential therapeutic modulator for atherosclerosis.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
01:30Atherosclerosis I: Introduction
01:38Inflammation